retatrutide type 2 diabetes 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide vs Tirzepatide (2026): Differences

Monitoring and Data Collection Robust data collection is fundamental to assessing the effects of any peptide or stack

Retatrutide hits three receptors: GLP-1, GIP, and glucagon

About HRS9531 (KAI-9531) HRS9531 is a dual GLP-1/GIP receptor agonist in development as an injectable peptide for type 2 diabetes, obesity and related metabolic conditions

Nausea is the single most common side effect of GLP-1 receptor agonist medications and the most common reason patients in clinical trials and in clinic discontinue treatment

"I use a lot of GLP-1s because they are shown to reduce the risk of dying from heart disease by up to 20% depending on the population

While this new pill is a game-changer, it is a medical treatment intended for specific individuals